Literature DB >> 9665382

MHC class I expression in murine skin: developmentally controlled and strikingly restricted intraepithelial expression during hair follicle morphogenesis and cycling, and response to cytokine treatment in vivo.

R Rückert1, U Hofmann, C van der Veen, S Bulfone-Paus, R Paus.   

Abstract

Hair bulb keratinocytes generate one of the few "immune privileged" tissue compartments of the mammalian organism by suppressing classical MHC class I (MHC Ia) antigens. Expression of non-classical MHC class I (MHC Ib) antigens in the follicle has been found, but only in its distal epithelium. Here, we have defined when during murine hair follicle morphogenesis these peculiar MHC Ia and Ib expression patterns are established, how they change during the murine hair cycle, and how different MHC I modulatory agents alter follicular MHC Ia and Ib expression in vivo. During neonatal hair follicle morphogenesis in C57BL/6 mice, distal follicle keratinocytes began to express MHC Ia (H2b) only late in development. The MHC Ib antigens, Qa-1 and Qa-2, did not become visible until the initiation of follicle cycling, with Qa-1 expression being more widespread than that of Qa-2. H2b, Qa-1, and TAP-1 immunoreactivity on previously negative keratinocytes of the proximal anagen hair bulb was upregulated by intradermal injection of the proinflammatory cytokine interferon-gamma, but not by tumor necrosis factor-alpha or interleukin-1beta. Injection of the reportedly MHC class I downregulating agents interleukin-10, insulin-like growth factor-1, transforming growth factor-beta, alpha-melanocyte stimulating hormone, or dexamethasone, however, all failed to downregulate constitutive or interferon-gamma-induced follicular MHC Ia expression. This shows that the hair follicle is a previously unrecognized site of Qa-1 expression and that interferon-gamma is a key regulator of follicular MHC I expression in vivo. It also suggests that the developmental and immunologic controls of MHC I expression by follicle keratinocytes differ from those of other epithelial cells.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9665382     DOI: 10.1046/j.1523-1747.1998.00228.x

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  13 in total

1.  Collapse and restoration of MHC class-I-dependent immune privilege: exploiting the human hair follicle as a model.

Authors:  Taisuke Ito; Natsuho Ito; Albrecht Bettermann; Yoshiki Tokura; Masahiro Takigawa; Ralf Paus
Journal:  Am J Pathol       Date:  2004-02       Impact factor: 4.307

Review 2.  The role of lymphocytes in the development and treatment of alopecia areata.

Authors:  Hongwei Guo; Yabin Cheng; Jerry Shapiro; Kevin McElwee
Journal:  Expert Rev Clin Immunol       Date:  2015-09-07       Impact factor: 4.473

Review 3.  Lymphocytes, neuropeptides, and genes involved in alopecia areata.

Authors:  Amos Gilhar; Ralf Paus; Richard S Kalish
Journal:  J Clin Invest       Date:  2007-08       Impact factor: 14.808

4.  CXCR3 Blockade Inhibits T Cell Migration into the Skin and Prevents Development of Alopecia Areata.

Authors:  Zhenpeng Dai; Luzhou Xing; Jane Cerise; Eddy Hsi Chun Wang; Ali Jabbari; Annemieke de Jong; Lynn Petukhova; Angela M Christiano; Raphael Clynes
Journal:  J Immunol       Date:  2016-07-13       Impact factor: 5.422

Review 5.  Immune Privilege Collapse and Alopecia Development: Is Stress a Factor.

Authors:  Soraya Azzawi; Lauren R Penzi; Maryanne M Senna
Journal:  Skin Appendage Disord       Date:  2017-12-20

Review 6.  Alopecia areata: a review on diagnosis, immunological etiopathogenesis and treatment options.

Authors:  A Sterkens; J Lambert; A Bervoets
Journal:  Clin Exp Med       Date:  2021-01-01       Impact factor: 3.984

7.  Expression of CD1d in human scalp skin and hair follicles: hair cycle related alterations.

Authors:  M A Adly; M A Adley; H A Assaf; M Hussein
Journal:  J Clin Pathol       Date:  2005-12       Impact factor: 3.411

8.  Effective melanoma immunotherapy in mice by the skin-depigmenting agent monobenzone and the adjuvants imiquimod and CpG.

Authors:  Jasper G van den Boorn; Debby Konijnenberg; Esther P M Tjin; Daisy I Picavet; Nico J Meeuwenoord; Dmitri V Filippov; J P Wietze van der Veen; Jan D Bos; Cornelis J M Melief; Rosalie M Luiten
Journal:  PLoS One       Date:  2010-05-13       Impact factor: 3.240

Review 9.  What causes alopecia areata?

Authors:  K J McElwee; A Gilhar; D J Tobin; Y Ramot; J P Sundberg; M Nakamura; M Bertolini; S Inui; Y Tokura; L E King; B Duque-Estrada; A Tosti; A Keren; S Itami; Y Shoenfeld; A Zlotogorski; R Paus
Journal:  Exp Dermatol       Date:  2013-09       Impact factor: 3.960

10.  A Cell Membrane-Level Approach to Cicatricial Alopecia Management: Is Caveolin-1 a Viable Therapeutic Target in Frontal Fibrosing Alopecia?

Authors:  Ivan Jozic; Jérémy Chéret; Beatriz Abdo Abujamra; Mariya Miteva; Jennifer Gherardini; Ralf Paus
Journal:  Biomedicines       Date:  2021-05-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.